MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma: an evaluation of the multicenter prospective skin cancer registry ADOREG
Objectives - Forty to sixty percent of patients with advanced melanoma show primary resistance to PD-1-based immunotherapy, 30-40% of initial responders also progress. Here, we evaluated the outcome of second-line targeted therapy (TT) after progression on PD-1-based immune checkpoint inhibition (IC...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 2022
|
| In: |
European journal of cancer
Year: 2022, Jahrgang: 167, Pages: 32-41 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2022.02.023 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2022.02.023 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804922001216 
|
| Verfasserangaben: | Sophia Kreft, Valerie Glutsch, Anne Zaremba, Patrick Schummer, Peter Mohr, Imke Grimmelmann, Ralf Gutzmer, Friedegund Meier, Claudia Pföhler, Michael Max Sachse, Frank Meiss, Andrea Forschner, Sebastian Haferkamp, Julia Welzel, Patrick Terheyden, Rudolf Herbst, Jochen Utikal, Martin Kaatz, Carsten Weishaupt, Alexander Kreuter, Dirk Debus, Pia Duecker, Anca Sindrilaru, Harald Löffler, Gaston Schley, Michael Weichenthal, Dirk Schadendorf, Selma Ugurel, Anja Gesierich, Bastian Schilling |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1902596145 | ||
| 003 | DE-627 | ||
| 005 | 20251111094409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240916s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2022.02.023 |2 doi | |
| 035 | |a (DE-627)1902596145 | ||
| 035 | |a (DE-599)KXP1902596145 | ||
| 035 | |a (OCoLC)1475311857 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kreft, Sophia |d 1994- |e VerfasserIn |0 (DE-588)1193611040 |0 (DE-627)1672357802 |4 aut | |
| 245 | 1 | 0 | |a MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma |b an evaluation of the multicenter prospective skin cancer registry ADOREG |c Sophia Kreft, Valerie Glutsch, Anne Zaremba, Patrick Schummer, Peter Mohr, Imke Grimmelmann, Ralf Gutzmer, Friedegund Meier, Claudia Pföhler, Michael Max Sachse, Frank Meiss, Andrea Forschner, Sebastian Haferkamp, Julia Welzel, Patrick Terheyden, Rudolf Herbst, Jochen Utikal, Martin Kaatz, Carsten Weishaupt, Alexander Kreuter, Dirk Debus, Pia Duecker, Anca Sindrilaru, Harald Löffler, Gaston Schley, Michael Weichenthal, Dirk Schadendorf, Selma Ugurel, Anja Gesierich, Bastian Schilling |
| 264 | 1 | |c May 2022 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 30. März 2022, Artikelversion: 30. März 2022 | ||
| 500 | |a Gesehen am 16.09.2024 | ||
| 520 | |a Objectives - Forty to sixty percent of patients with advanced melanoma show primary resistance to PD-1-based immunotherapy, 30-40% of initial responders also progress. Here, we evaluated the outcome of second-line targeted therapy (TT) after progression on PD-1-based immune checkpoint inhibition (ICI) in BRAFV600-mutated melanoma. In addition, we report data on the activity of re-exposure with PD-1-based regimes. - Methods - Patients with advanced (non-resectable stage III or IV, AJCC 2017, 8th edition) melanoma progressing on PD-1-based ICI (nivolumab, pembrolizumab or ipilimumab plus nivolumab) and receiving second-line BRAF plus MEK inhibition were identified from the prospective multicenter skin cancer registry ADOREG. - Results - We identified 108 patients with unresectable stage III or stage IV melanoma progressing on first-line ICI (nivolumab, pembrolizumab or ipilimumab plus nivolumab) and receiving second-line combined BRAF/MEK inhibition. Seventy-three percent of the cohort presented with primary PD-1 resistant disease. Median progression-free survival (PFS) on ICI was 2.6 (95% CI 2.2-2.9) months. Median PFS on subsequent TT was 6.6 (95% CI 5.4-7.8) months. Median OS from start of second-line TT was 16.0 (95% CI 11.2-20.8) months. The 3-year PFS and OS rates on second-line TT were 16% and 30%. The objective response rate (ORR) and disease control rate (DCR) to TT were 42.6% and 55.6%. In patients with brain metastases, the ORR and DCR were 31.4% and 43.1%. Patients without brain metastases showed an ORR and DCR of 52.6% and 66.7%, respectively. Response to first-line ICI was associated with a numerically higher ORR and DCR to second-line TT and improved OS on TT. Twenty-three patients received third-line ICI of whom two patients showed an objective response. - Conclusions - BRAF plus MEK inhibition shows meaningful activity and outcome in patients with advanced melanoma resistant to anti-PD-1-based immunotherapy. Rates of long-term benefit and survival in our study were similar to those reported for treatment-naïve patients receiving first-line MAPKi. | ||
| 650 | 4 | |a MAPK | |
| 650 | 4 | |a Melanoma | |
| 650 | 4 | |a PD-1 resistance | |
| 650 | 4 | |a Second-line treatment | |
| 650 | 4 | |a Third-line treatment | |
| 700 | 1 | |a Glutsch, Valerie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zaremba, Anne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schummer, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mohr, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grimmelmann, Imke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gutzmer, Ralf |d 1968- |e VerfasserIn |0 (DE-588)113713371 |0 (DE-627)502213558 |0 (DE-576)289772095 |4 aut | |
| 700 | 1 | |a Meier, Friedegund |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pföhler, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sachse, Michael Max |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Meiß, Frank |d 1975- |e VerfasserIn |0 (DE-588)128821825 |0 (DE-627)70707617X |0 (DE-576)297349635 |4 aut | |
| 700 | 1 | |a Forschner, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haferkamp, Sebastian |d 1978- |e VerfasserIn |0 (DE-588)132018330 |0 (DE-627)51684296X |0 (DE-576)298896044 |4 aut | |
| 700 | 1 | |a Welzel, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Terheyden, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herbst, Rudolf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 700 | 1 | |a Kaatz, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weishaupt, Carsten |d 1973- |e VerfasserIn |0 (DE-588)130499129 |0 (DE-627)502596430 |0 (DE-576)298232898 |4 aut | |
| 700 | 1 | |a Kreuter, Alexander |d 1971- |e VerfasserIn |0 (DE-588)132383993 |0 (DE-627)521950546 |0 (DE-576)299112063 |4 aut | |
| 700 | 1 | |a Debus, Dirk |d 1974- |e VerfasserIn |0 (DE-588)129113980 |0 (DE-627)389664723 |0 (DE-576)297500732 |4 aut | |
| 700 | 1 | |a Duecker, Pia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sindrilaru, Anca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Löffler, Harald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schley, Gaston |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weichenthal, Michael |e VerfasserIn |0 (DE-588)140953272 |0 (DE-627)623003848 |0 (DE-576)321514157 |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 700 | 1 | |a Ugurel, Selma |d 1971- |e VerfasserIn |0 (DE-588)122030923 |0 (DE-627)081693532 |0 (DE-576)293057567 |4 aut | |
| 700 | 1 | |a Gesierich, Anja |e VerfasserIn |4 aut | |
| 700 | 1 | |8 2\p |a Schilling, Bastian |d 1979- |e VerfasserIn |0 (DE-588)142513563 |0 (DE-627)704247887 |0 (DE-576)331358913 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 167(2022) vom: Mai, Seite 32-41 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma an evaluation of the multicenter prospective skin cancer registry ADOREG |
| 773 | 1 | 8 | |g volume:167 |g year:2022 |g month:05 |g pages:32-41 |g extent:10 |a MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma an evaluation of the multicenter prospective skin cancer registry ADOREG |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2022.02.023 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804922001216 |x Verlag |z kostenfrei |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20240916 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 122030923 |a Ugurel, Selma |m 122030923:Ugurel, Selma |d 60000 |e 60000PU122030923 |k 0/60000/ |p 28 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 27 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 17 | ||
| 999 | |a KXP-PPN1902596145 |e 4580273583 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"May 2022"}],"language":["eng"],"physDesc":[{"extent":"10 S."}],"person":[{"display":"Kreft, Sophia","role":"aut","given":"Sophia","roleDisplay":"VerfasserIn","family":"Kreft"},{"roleDisplay":"VerfasserIn","family":"Glutsch","given":"Valerie","display":"Glutsch, Valerie","role":"aut"},{"role":"aut","display":"Zaremba, Anne","given":"Anne","family":"Zaremba","roleDisplay":"VerfasserIn"},{"given":"Patrick","role":"aut","display":"Schummer, Patrick","family":"Schummer","roleDisplay":"VerfasserIn"},{"family":"Mohr","roleDisplay":"VerfasserIn","given":"Peter","role":"aut","display":"Mohr, Peter"},{"roleDisplay":"VerfasserIn","family":"Grimmelmann","given":"Imke","display":"Grimmelmann, Imke","role":"aut"},{"family":"Gutzmer","roleDisplay":"VerfasserIn","given":"Ralf","display":"Gutzmer, Ralf","role":"aut"},{"given":"Friedegund","display":"Meier, Friedegund","role":"aut","family":"Meier","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Pföhler","given":"Claudia","display":"Pföhler, Claudia","role":"aut"},{"given":"Michael Max","role":"aut","display":"Sachse, Michael Max","roleDisplay":"VerfasserIn","family":"Sachse"},{"given":"Frank","display":"Meiß, Frank","role":"aut","roleDisplay":"VerfasserIn","family":"Meiß"},{"family":"Forschner","roleDisplay":"VerfasserIn","given":"Andrea","display":"Forschner, Andrea","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Haferkamp","role":"aut","display":"Haferkamp, Sebastian","given":"Sebastian"},{"given":"Julia","display":"Welzel, Julia","role":"aut","family":"Welzel","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Terheyden, Patrick","given":"Patrick","roleDisplay":"VerfasserIn","family":"Terheyden"},{"family":"Herbst","roleDisplay":"VerfasserIn","given":"Rudolf","role":"aut","display":"Herbst, Rudolf"},{"roleDisplay":"VerfasserIn","family":"Utikal","display":"Utikal, Jochen","role":"aut","given":"Jochen"},{"role":"aut","display":"Kaatz, Martin","given":"Martin","roleDisplay":"VerfasserIn","family":"Kaatz"},{"roleDisplay":"VerfasserIn","family":"Weishaupt","display":"Weishaupt, Carsten","role":"aut","given":"Carsten"},{"given":"Alexander","display":"Kreuter, Alexander","role":"aut","roleDisplay":"VerfasserIn","family":"Kreuter"},{"family":"Debus","roleDisplay":"VerfasserIn","given":"Dirk","role":"aut","display":"Debus, Dirk"},{"family":"Duecker","roleDisplay":"VerfasserIn","role":"aut","display":"Duecker, Pia","given":"Pia"},{"family":"Sindrilaru","roleDisplay":"VerfasserIn","given":"Anca","role":"aut","display":"Sindrilaru, Anca"},{"roleDisplay":"VerfasserIn","family":"Löffler","display":"Löffler, Harald","role":"aut","given":"Harald"},{"given":"Gaston","role":"aut","display":"Schley, Gaston","family":"Schley","roleDisplay":"VerfasserIn"},{"given":"Michael","role":"aut","display":"Weichenthal, Michael","roleDisplay":"VerfasserIn","family":"Weichenthal"},{"given":"Dirk","display":"Schadendorf, Dirk","role":"aut","family":"Schadendorf","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Ugurel","role":"aut","display":"Ugurel, Selma","given":"Selma"},{"given":"Anja","role":"aut","display":"Gesierich, Anja","family":"Gesierich","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Schilling","given":"Bastian","display":"Schilling, Bastian","role":"aut"}],"name":{"displayForm":["Sophia Kreft, Valerie Glutsch, Anne Zaremba, Patrick Schummer, Peter Mohr, Imke Grimmelmann, Ralf Gutzmer, Friedegund Meier, Claudia Pföhler, Michael Max Sachse, Frank Meiss, Andrea Forschner, Sebastian Haferkamp, Julia Welzel, Patrick Terheyden, Rudolf Herbst, Jochen Utikal, Martin Kaatz, Carsten Weishaupt, Alexander Kreuter, Dirk Debus, Pia Duecker, Anca Sindrilaru, Harald Löffler, Gaston Schley, Michael Weichenthal, Dirk Schadendorf, Selma Ugurel, Anja Gesierich, Bastian Schilling"]},"relHost":[{"part":{"text":"167(2022) vom: Mai, Seite 32-41","volume":"167","year":"2022","extent":"10","pages":"32-41"},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"1992-","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press"}],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"id":{"issn":["1879-0852"],"zdb":["1468190-0"],"eki":["266883400"]},"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"disp":"MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma an evaluation of the multicenter prospective skin cancer registry ADOREGEuropean journal of cancer","titleAlt":[{"title":"EJC online"}],"pubHistory":["28.1992 -"],"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"roleDisplay":"Herausgebendes Organ","display":"European Association for Cancer Research","role":"isb"},{"role":"isb","display":"European School of Oncology","roleDisplay":"Herausgebendes Organ"}],"recId":"266883400"}],"recId":"1902596145","id":{"doi":["10.1016/j.ejca.2022.02.023"],"eki":["1902596145"]},"title":[{"subtitle":"an evaluation of the multicenter prospective skin cancer registry ADOREG","title_sort":"MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma","title":"MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma"}],"note":["Online verfügbar: 30. März 2022, Artikelversion: 30. März 2022","Gesehen am 16.09.2024"]} | ||
| SRT | |a KREFTSOPHIMAPKINASEI2022 | ||